Equivalent of Form PTO/SB/08A (09-06) Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

titute for form 1449/PTO

1 of

STEW &

Sheet

(Use as many sheets as necessary)

Under the Paperwork Reduction Act of 1995, no	persons are required to respond to a collection	on of information unless it contains a valid OMB control number				
1449/PTO	Complete i	Complete if Known				
	Application Number	10/564,744				
ION DISCLOSURE	§ 371 Date	March 3, 2006				
IT BY APPLICANT	First Named Inventor	GARDELLA, Thomas J.				
many sheets as necessary)	Art Unit	1654				
	Examiner Name	Gupta, Anish				
of 1	Attorney Docket Number	0609.5160001/TJS/PAC/JJY				

			U.S. PATENT DO	OCUMENTS		
Examiner Cite Initials No.		Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Number-Kind Code ^{2 (If Kao}	Number-Kind Code ^{2 (If Known)}					
	USI	4,675,189	06/23/1987	Kent et al.		
-						
			-			
			ļ			
			ļ			
			1			

		Fo	REIGN PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
		Country Code ³ Number ⁴ Kind Code ³ (if known)			Relevant Passages or Relevant Figures Appear	T ⁶
						Ш
						Ш
						Ш
						Ш
						Ш
						Ш
					ļ	ш
					L	\sqcup

652722v1

	Date	
	2	
	Considered	
l .	Combiacióa	
		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique to extend designation number (oplicant). See Kinds Codes of USFIO Pattern Documents at two wuspio, op or MFEP 90104. Finer Office that issued the document on the two the code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriates symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to camplete, including gathering, preparing, and submitting the competed application form to the USPTO. There will vay depending upon the includical cases. Any comments on the amount of time you require to complete this form and/or suggestions for reducing in this burden, should be sent to the Cheff Information Officer, U.S. Patent and Trademark Office, P.O. 80x 1450, Alexandrie, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandrie, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandrie, VA 22313-1450.

6Equivalent of Form PTO/SB/08B (09-06) Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless it contains a valid OMB control number.

tute f	or form 14	49/PTO		Compl	Complete if Known			
				Application Number	10/564,744			
INFOR	MATIC	ON DISC	CLOSURE	§ 371 Date	March 3, 2006			
STATE	MENT	BY AP	PLICANT	First Named Inventor GARDELLA, Thomas J.				
	(Use as	s many sheets	as necessary)	Art Unit	1654			
				Examiner Name	Gupta, Anish			
Sheet	1	of	4	Attorney Docket Number	0609.5160001/TJS/PAC/JJY			

NON PATENT LITERATURE DOCUMENTS

Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	Barden, J.A. and Kemp, B.E., "NMR Solution Structure of Human Parathyroid Hormone(1-34)," <i>Biochemistry</i> 32:7126-7132, American Chemical Society (1993)	
	NPL2	Behar, V., et al., "Photoaffinity Cross-linking Identifies Differences in the Interactions of an Agonist and an Antagonist with the Parathyroid Hormone/Parathyroid Hormone-related Protein Receptor," J. Biol. Chem. 275:9-17, American Society for Biochemistry and Molecular Biology, Inc. (2000)	
	NPL3	Bergwitz, C., et al., "Full Activation of Chimeric Receptors by Hybrids between Parathyroid Hormone and Calcitonin," J. Biol. Chem. 271:26469-26472, The American Society for Biochemistry and Molecular Biology, Inc. (1996)	
	NPL4	Berridge, M.J., et al., "Changes in the levels of inositol phosphates after agonist- dependent hydrolysis of membrane phosphoinositides," <i>Biochem. J.</i> 212:473- 482, The Biochemical Society (1983)	
	NPL5	Bisello, A., et al., "Parathyroid Hormone-Receptor Interactions Identified Directly by Photocross-linking and Molecular Modeling Studies," J. Biol. Chem. 273:22498-22505, The American Society for Biochemistry and Molecular Biology, Inc. (1998)	
	NPL6	Carter, P.H and Gardella, T.J., "Zinc(II)-mediated enhancement of the agonist activity of histidine-substituted parathyroid hormone(1-14) analogues," <i>Biochem. Biophys. Acta</i> 1538:290-304, Elsevier Science B.V. (2001)	
	NPL7	Chen, Z., et al., "Structure of the Osteogenic 1-31 Fragment of Human Parathyroid Hormone," <i>Biochemistry 39</i> :12766-12777, American Chemical Society (2000)	
	NPL8	Condon, S.M., et al., "The Bioactive Conformation of Human Parathyroid Hormone. Structural Evidence for the Extended Helix Postulate," J. Am. Chem. Soc. 122:3007-3014, American Chemical Society (2000)	
	NPL9	Creighton, T.E., ed., "3.2. Evolutionary Divergence of Proteins," in: <i>Proteins: Structures and Molecular Properties</i> , 2 nd Ed., W.H. Freeman and Co., NewYork, NY, pp 108-114 (1993)	
665208v1	NPL10	Dempster, D.W., et al., "Anabolic Actions of Parathyroid Hormone on Bone," Endocrine Rev. 14:690-709, The Endocrine Society (1993)	

NON PATENT LITERATURE DOCUMENTS

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

[&]quot;ExAMINER: Initial if reference considered, whether or not clation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

'Applicant is unique citation designation number (optional). 'Applicant is to place a check mark here if English language Trails in a statement of the property of the problem of comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND TO COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

6Equivalent of Form PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number

for form 1449/PTO

NPL19

				Application Number	10/364,744			
INFORI	MATIO	N DISC	CLOSURE	§ 371 Date	March 3, 2006			
STATE	MENT	BY AP	PLICANT	First Named Inventor	GARDELLA, Thomas J.			
	(Use as	nany sheets	as necessary)	Art Unit	1654			
				Examiner Name	Gupta, Anish			
Sheet	2	of	4	Attorney Docket Number	0609.5160001/TJS/PAC/J	ĴΥ		
Examiner Initials*	Cite No.1		he item (book, magazine, j	CAPITAL LETTERS), title of the art ournal, serial, symposium, catalog, of blisher, city and/or country where po	etc.), date, page(s), volume	T²		
	NPL11			rratum: Anabolic Actions of P 261, The Endocrine Society (
	NPL12	Postr	nenopausal Women w	Mechanism of Cancellous Bon with Mild Primary Hyperparath sm 84:1562-1566, The Endoc	nyroidism," J. Clinical			
	NPL13	Char	Fairwell, T., et al., "Total Solid-Phase Synthesis, Purification, and Characterization of Human Parathyroid Hormone-(1-84)," Biochemistry 22:2691-2697, American Chemical Society (1983)					
*	NPL14	Bind	Gardella, T.J., et al., "Analysis of Parathyroid Hormone's Principal Receptor Binding Region by Site-Directed Mutagenesis and Analog Design," <i>Endocrinol.</i> 132:2024-2030, Endocrine Society (1993)					
	NPL1	in So	Gronwald, W., et al., "Structure of Recombinant Human Parathyroid Hormone in Solution Using Multidimensional NMR Spectroscopy," Chem. Hoppe-Seyler 377:175-186, Walter de Gruyter & Co. (1996)					
	NPL16	Parat	Goud, N.A., et al., "Solid-Phase Synthesis and Biologic Activity of Human Parathyroid Hormone(1-84)," J. Bone Min. Res. 6:781-789, Mary Ann Liebert, Inc. (1991)					
	NPL17	Parat	Hoare, S.R.J., et al., "Evaluating the Signal Transduction Mechanism of the Parathyroid Hormone 1 Receptor," J. Biol. Chem. 276:7741-7753, American Society for Biochemistry and Molecular Biology (2001)					
	NPL18		Jin, L., et al., "Crystal Structure of Human Parathyroid Hormone 1-34 at 0.9-Å Resolution," J. Biol. Chem. 275:27238-27244, The American Society for					

NON PATENT LITERATURE DOCUMENTS

Jüppner, H., et al., "A G Protein-Linked Receptor for Parathyroid Hormone and

Parathyroid Hormone-Related Peptide," Science 254:1024-1026, American

Biochemistry and Molecular Biology, Inc. (2000)

Society for the Advancement of Science (1991)

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (pointed). Applicant's unique citation designation number (pointed). Applicant's unique citation designation number (pointed). Applicant's unique citation designation number (pointed).

This collection of Information is required by 37 CFR 198. The Information is required to obtain or retain a benefit by the public which is to fit (and by the USFTO to process) an application. Confidentiality is governed by 38 U.S. C. 122 and 37 CFR 1.1. This collection is elabor to take 2 hours to complete, including pathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chef Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 4450, Alexandria, VA 22313-1450.

6Equivalent of Form PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number e for form 1449/PTO Complete if Known 10/564 744 Application Number INFORMATION DISCLOSURE 8 371 Date March 3, 2006 STATEMENT BY APPLICANT First Named Inventor GARDELLA, Thomas J. (Use as many sheets as necessary) Art I Init 1654 Examiner Name Gupta, Anish Attorney Docket Number 0609.5160001/TJS/PAC/JJY Sheet of Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title Examiner Cite T² Initials* No.1 of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published Kronenberg, H.M., et al., "Parathyroid Hormone: Biosynthesis, Secretion, Chemistry, and Action" in: Handbook of Experimental Pharmacology, Mundy, NPI 20 G.R., and Martin, T.J., eds., Springer-Verlag, Berlin, Germany, pp. 507-567 Luck, M.D., et al., "The (1-14) Fragment of Parathyroid Hormone (PTH) NPL21 Activates Intact and Amino-Terminally Truncated PTH-1 Receptors." Mol. Endocrinol, 13:670-680, The Endocrine Society (1999) Marx, U.C., et al., "Structure of Human Parathyroid Hormone 1-37 in Solution." NPI 22 J. Biol. Chem. 270:15194-15202. The American Society for Biochemistry and Molecular Biology, Inc. (1995) Marx, U.C., et al., "Structure Activity Relation of NH2-Terminal Human NPI.23 Parathyroid Hormone Fragments," J. Biol. Chem 273:4308-4316, American Society for Biochemistry and Molecular Biology, Inc. (1998) Marx, U.C., et al., "Solution Structure of Human Parathyroid Hormone Fragments hPTH(1-34) and hPTH (1-39) and Bovine Parathyroid Hormone NPI.24 Fragment bPTH(1-37)," Biochem, Biophys, Res. Commun. 267:213-220. Academic Press (2000) Neer, R.M., et al., "Effect of Parathyroid Hormone (1-34) on Fractures and NPL25 Bone Mineral Density in Postmenopausal Women with Osteoporosis," N. Eng. J. Med. 344:1434-1441, Massachusetts Medical Society (2001) Pellegrini, M., et al., "Binding Domain of Human Parathyroid Hormone NPL26 Receptor: From Conformation to Function," Biochemistry 37:12737-12743. American Chemical Society (1998) Robinson J.R. ed., "Methods to Achieve Controlled Drug Delivery," in: NPL27 Sustained and Controlled Release Drug Delivery Systems, Marcel Dekker, New York, NY, pp 557-593 (1978) Rölz, C. and Mierke, D.F., "Characterization of the molecular motions of NPL28 constitutively active G protein-coupled receptors for parathyroid hormone," Biophys. Chem. 89:119-128, Elsevier Science B.V. (2001) Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title Examiner No 1 T2 Initials* of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published

Examiner	Date	
Signature	Considered	a i i

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or training to make the state that USPTO is processed, an application, Confidentiality is governed by 38 U.S. C. 122 and 37 CFR 1.14. This collection is eliminated for this 28 owns to complete, under the complete state of the collection is elementated for this 28 owns to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be set to the Chef Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 4450, Alexandria, VA 22313-1450.



Substitute for form 1449/PTO Complete if Known Application Number 10/564.744 INFORMATION DISCLOSURE § 371 Date March 3, 2006 STATEMENT BY APPLICANT First Named Inventor GARDELLA, Thomas J. Art Unit (Use as many sheets as necessary) 1654 Examiner Name Gupta, Anish Attorney Docket Number 0609 5160001/TIS/PAC/JIY Sheet of Shimizu, M., et al., "Autoactivation of Type-1 Parathyroid Hormone Receptors NPL29 Containing a Tethered Ligand," J. Biol. Chem. 275:19456-19460, The American Society for Biochemistry and Molecular Biology, Inc. (2000) Shimizu, M., et al., "Minimization of Parathyroid Hormone," J. Biol. Chem. NPL30 275:21836-21834. The American Society for Biochemistry and Molecular Biology, Inc. (2000) Shimizu, M., et al., "Enhanced Activity in Parathyroid Hormone-(1-14) and -(1-NPL31 11): Novel Peptides for Probing Ligand-Receptor Interactions," Endocrinol. 142:3068-3074, Endocrine Society (2001) Shimizu, N., et al., "Parathyroid Hormone (PTH)-(1-14) and -(1-11) Analogs Conformationally Constrained by \alpha-Aminosobutyric Acid Mediate Full Agonist NPI.32 Responses via the Juxtamembrane Region of the PTH-1 Receptor," J. Biol. Chem. 276:49003-49012, The American Society for Biochemistry and Molecular Biology, Inc. (2001) Slovik, D.M., et al., "Restoration of Spinal Bone in Osteoporotic Men by Treatment with Human Parathyroid Hormone (1-34) and 1,25-NPL33 Dihydroxyvitamin D," J. Bone Min. Res. 1:377-381, Mary Ann Liebert, Inc. Takasu, H., et al., "Amino Terminal Modifications of Human Parathyroid Hormone (PTH) Selectively Alter Phospholipase C Signaling via The Type 1 **NPI 34** PTH Receptor: Implications of Design of Signal-Specific PTH Ligands." Biochemistry 38:13453-13460, American Chemical Society (1999) Tregear, G.W., et al., "Bovine Parathyroid Hormone: Minimum Chain Length NPL35 of Synthetic Peptide Required for Biological Activity," Endocrinol. 93:1349-1353, The Endocrine Society (1973) Wold, F., "Posttranslational Protein Modifications: Perspectives and Prospects." NPI.36 in Posttranslational Covalent Modifications of Proteins, B.C. Johnson, eds., Academic Press, Inc., New York, pp. 1-12 (1983)

Examiner	Date	
Signature	Considered	
		l .

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional) *Applicant's unique citation designation optional option

This collection of information is required by 37 CFR 198. The information is required to obtain or retain a benefit by this public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 38 U.S. C. 122 and 37 CFR 1.14. This collection is estimate to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing his burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 4450, Alexandria, VA 22313-1450.